However, since the establishment of Ki-67 as a prognostic variable in breast cancer, the more pertinent question from a clinical perspective has become the need to better define cutoff points along the Ki-67 expression continuum, such that breast cancer patients can be more consistently and accurately stratified into groups with higher and lower risk of recurrence as well as those more and less likely to benefit from systemic treatments. The gene discussed is MKI67; the disease is breast carcinoma.